Document
IPR2023-00724, No. 1004 Exhibit - Bantle CV (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1004 Exhibit - Bantle CV (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 2371 Exhibit - EX2371 US Food Drug Administration, DrugsFDA, Prandin® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2371 Exhibit - EX2371 US Food Drug Administration, DrugsFDA, Prandin® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2533 Exhibit - EX2533 Novo Nordisk seeks partners within (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2533 Exhibit - EX2533 Novo Nordisk seeks partners within (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2480 Exhibit - EX2480 IQVIA, About us, httpswwwiqviacomabout us (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2480 Exhibit - EX2480 IQVIA, About us, httpswwwiqviacomabout us (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2082 Exhibit - EX2082 MS Capehorn et al, “Efficacy and safety of once weekly semaglutide 10 mg vs once daily liraglutide 12 mg as add on to 1 3 oral antidiabetic drugs in s...
Cite Document
IPR2023-00724, No. 2082 Exhibit - EX2082 MS Capehorn et al, “Efficacy and safety of once weekly semaglutide 10 mg vs once daily liraglutide 12 mg as add on to 1 3 oral antidiabetic drugs in subjects
+ More Snippets
Document
IPR2023-00724, No. 2406 Exhibit - EX2406 Aurobindo, “Aurobindo Received FDA Approval for Saxagliptin Tablets, 25mg and 5mg,” httpswwwaurobindousacomnewsproduct newsaurobindo rec...
Cite Document
IPR2023-00724, No. 2406 Exhibit - EX2406 Aurobindo, “Aurobindo Received FDA Approval for Saxagliptin Tablets, 25mg and 5mg,” httpswwwaurobindousacomnewsproduct newsaurobindo receives fda approval fo
+ More Snippets
Document
IPR2023-00724, No. 2003 Exhibit - EX2003 Excerpt of Amended Joint Claim Construction Chart, In re Ozempic Semaglutide Patent Litigation, No 122 cv 01040 CFC, Dkt 101 D Del May 23, 2023...
Cite Document
IPR2023-00724, No. 2003 Exhibit - EX2003 Excerpt of Amended Joint Claim Construction Chart, In re Ozempic Semaglutide Patent Litigation, No 122 cv 01040 CFC, Dkt 101 D Del May 23, 2023 (P.T.A.B. Jul
+ More Snippets
Document
IPR2023-00724, No. 2610 Exhibit - EX2610 Trackdrugscom Homepage Marked As Exhibit 2610 at DeForest McDuff Deposition (P.T.A.B. Aug. 5, 2024)
Cite Document
IPR2023-00724, No. 2610 Exhibit - EX2610 Trackdrugscom Homepage Marked As Exhibit 2610 at DeForest McDuff Deposition (P.T.A.B. Aug. 5, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1144 Exhibit - Exhibit 1144 Holz (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1144 Exhibit - Exhibit 1144 Holz (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1126 Exhibit - Exhibit 1126 Pratley (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1126 Exhibit - Exhibit 1126 Pratley (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1121 Exhibit - Exhibit 1121 833 patent (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1121 Exhibit - Exhibit 1121 833 patent (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1065 Exhibit - Tasneem 2012 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1065 Exhibit - Tasneem 2012 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1023 Exhibit - Drucker 2003 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1023 Exhibit - Drucker 2003 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1059 Exhibit - Murphy 2012 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1059 Exhibit - Murphy 2012 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1136 Exhibit - Exhibit 1136 Harrisons (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1136 Exhibit - Exhibit 1136 Harrisons (P.T.A.B. May. 22, 2024)
+ More Snippets